News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

MAP Pharmaceuticals, Inc. And Xemplar Pharmaceuticals LLC Sign Exclusive Manufacturing Deal For Innovative Tempo(TM) Inhaler Products


5/17/2006 11:02:14 AM

MOUNTAIN VIEW, Calif. and FALL RIVER, Mass., May 17 /PRNewswire/ -- MAP Pharmaceuticals, Inc., a leading developer of novel inhaled drug therapies, and Xemplar Pharmaceuticals LLC, a contract services company developing inhalation products, today announced the signing of an agreement under which Xemplar will serve as the exclusive manufacturer of MAP's proprietary Tempo(TM) Inhaler products. Under terms of the agreement, Xemplar will also be responsible for additional development activities, including process engineering for MAP's preclinical and clinical products.

"After examining a variety of commercial manufacturing options, MAP decided that expanding its current developmental relationship with Xemplar best serves the company strategically," said Timothy Nelson, CEO of MAP Pharmaceuticals. "Xemplar has proven to be a high-quality and reliable commercial supplier and we are especially pleased by the company's willingness to provide MAP a priority manufacturing position within its operations."

As part of the agreement, MAP will provide an interim, interest free loan, as well as funding for technical assistance to Xemplar to support the expansion of the company's existing production facility. Xemplar will add approximately 12,000 square feet of commercial space designed specifically for the production of pressurized metered dose inhaler products, nasal sprays and dry powder inhalers.

Xemplar president Charles Eck and partners John and Richard Armstrong concur, "This agreement with MAP Pharmaceuticals is an exciting opportunity for both companies to make a significant step forward to reach their individual goals." Charles Eck stated, "Xemplar will now be able to provide necessary services to the pharmaceutical aerosol industry and at the same time, MAP will secure their product development and commercial needs. We at Xemplar celebrate this union."

Xemplar's initial product manufacturing activities are focused on Tempo Migraine, MAP's proprietary therapy for the treatment of migraine. Presently in Phase I clinical development, MAP expects to advance the product into Phase II trials in the United States later this year.

Xemplar will also be responsible for manufacturing additional Tempo-based therapeutics presently under development at MAP. These include products featuring a respiratory drug for the treatment of asthma and chronic obstructive pulmonary disease (COPD), as well as a drug commonly delivered systemically to treat metabolic disease.

About Tempo(TM)

MAP's Tempo(TM) Inhaler is a proprietary, breath synchronized plume controlled inhaler. Tempo automatically adjusts to each patient's unique inspiration pattern, without electronics, and is exceptionally easy to use, enhancing compliance. Tempo also features a novel aerosol flow controller that ensures efficient and consistent delivery to the lungs, reducing dose to dose variation while minimizing oral deposition of the delivered drug.

About MAP Pharmaceuticals, Inc.

Located in Mountain View, California, MAP Pharmaceuticals is a specialty pharmaceutical company focused on the development of innovative therapies and inhalation delivery systems to treat a broad range of respiratory and systemic diseases. MAP's lead product candidate is a proprietary formulation of budesonide for the treatment of asthma in both pediatric and adult populations. The Company is also developing a series of products based on its Tempo(TM) Inhaler platform, including a rapid-relief non-triptan treatment for migraine. Tempo is a proprietary, breath synchronized plume controlled inhaler. Tempo automatically adjusts to each patient's unique inspiration pattern, without electronics, and is exceptionally easy to use, enhancing compliance. Tempo also features a novel aerosol flow controller that ensures efficient and consistent delivery to the lungs, reducing dose to dose variation while minimizing oral deposition of the delivered drug. Additional information about MAP Pharmaceuticals can be found on our website at http://www.mappharma.com.

For more information, please e-mail: Lisa Johnson at ljohnson@mappharma.com.

About Xemplar Pharmaceuticals, LLC.

Xemplar Pharmaceuticals, located in a 24,000 square foot facility in Fall River, MA, is a contract services company focusing on the development of inhalation products including pMDIs, DPIs, LIs, nebules, buccal and nasal sprays. Although newly formed in July of 2002, Xemplar's expertise and experience is well known in the pharmaceutical aerosol industry where this laboratory has successfully competed under other names since 1994. Xemplar provides clients with the most sophisticated formulation, delivery and development technologies and product development support services to meet precise needs. Xemplar is among the first commercial facilities in the world to offer inhalation technologies development in conjunction with production of cGMP clinical supplies. The broad scientific experience of the staff ensures the effective development of a wide range of pharmaceutical and biopharmaceutical products.

For more information, please e-mail: Charles Eck at charles.eck@xemplarpharm.com.

MAP Pharmaceuticals, Inc.

CONTACT: Lisa Johnson, Media Contact of MAP Pharmaceuticals, Inc.,+1-650-386-3122, or ljohnson@mappharma.com; or Charles Eck of XemplarPharmaceuticals, LLC., +1-508-676-6726, or charles.eck@xemplarpharm.com


Read at BioSpace.com

comments powered by Disqus
   
Asthma

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES